Citigroup Maintains Raptor Pharmaceutical Corp. to Neutral with Price Target $8.00

Brokerage firm Citigroup Maintains its rating on Raptor Pharmaceutical Corp.(NASDAQ:RPTP). In a research note issued to the investors, the brokerage major Raises the price-target to $8.00 per share. The shares have been rated Neutral. The rating by Citigroup was issued on Aug 9, 2016.

In a different note, On Aug 8, 2016, Citigroup said it Downgrades its rating on Raptor Pharmaceutical Corp.. In the research note, the firm Raises the price-target to $6.00 per share. The shares have been rated ‘Neutral’ by the firm.

Raptor Pharmaceutical Corp. (RPTP) made into the market gainers list on Wednesdays trading session with the shares advancing 5.67% or 0.37 points. Due to strong positive momentum, the stock ended at $6.9, which is also near the day’s high of $7.39. The stock began the session at $6.54 and the volume stood at 55,22,949 shares. The 52-week high of the shares is $13.72 and the 52 week low is $2.94. The company has a current market capitalization of $589 M and it has 8,53,06,787 shares in outstanding.

Raptor Pharmaceutical Corp.(RPTP) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $32.05M. Analysts had an estimated revenue of $28.52M. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.18.

Several Insider Transactions has been reported to the SEC. On Sep 11, 2015, Suzanne Louise Bruhn (director) sold 18,258 shares at $12.47 per share price.Also, On Sep 4, 2015, Raymond Anderson (director) sold 4,916 shares at $12.51 per share price.On Jul 2, 2015, Llew Keltner (director) sold 50,000 shares at $16.05 per share price, according to the Form-4 filing with the securities and exchange commission.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe PROCYSBI gastro-resistant hard capsules of cysteamine received a marketing authorization from the European Commission (EC) as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine or RP103 and its oral 4-methylpyrazole or Convivia. Its other product Quinsair is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *